IAM Magazine issue 34

Valuing IP is complex, with more
than 50 different methods currently
in use. Given the growing
importance of IP to so many
organisations, perhaps now is the
time to re-think whether global
valuation standards make sense
Patrick Sullivan

Cellport Systems has thrived as a
small research-based business in a
market dominated by the big boys.
An innovative approach to patenting
plays a fundamental role in a
strategy that has created several
billion-dollar revenue streams
Pat Kennedy

Hewlett-Packard has devoted
significant time and resources to
ensuring that its IP portfolio is
aligned to the company’s overall
strategic goals. An extract from a
recently published book* about IP
business models explains how
Bruce Berman and Joe Beyers

The modern-day debate about IP is often
described as polarised and ideological.
Unfortunately, this may be too kind.
Many views are best described as naïve
and manipulative. The discourse on
counterfeiting and piracy is a good case
in point
Bowman J Heiden and Ulf Petrusson

Co-published editorialManagement report

Business method patents are still
alive and well in the United States.
However, the Federal Circuit’s
landmark Bilski decision is a
reminder that they must meet the
“machine-or-transformation” test,
like any other process claim.

A bill that would allow governmentfunded
academic institutions to
patent their inventions has received
a mixed reception. It should result in
greater interaction between
industry, academia and
government, but some fear it does
not protect the public interest

By implementing a sound and
flexible IP management process,
universities can spot the
technologies most suitable for
exploitation and give them a good
start in life. For those that do so,
there are rich rewards to be reaped

Co-published editorialIndustry insight

In today’s economic environment, it is
essential for law firms, like most other
businesses, to distinguish themselves
from their competitors in order to
maintain and grow market share, says
Steve Kriston, director of North American
sales for the Scientific business of
Thomson Reuters